Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660667 | 0.82 | CYP2A6 (0.40) | CYP2A6CCR1CCR8CYP11B2METAP2 | |
| SCHEMBL3664857 | 0.80 | CYP2A6 (0.38) | CYP2A6CCR1CCR8CYP11B2METAP2 | |
| SCHEMBL3662671 | 0.78 | EGFR (0.37) | CYP2A6CCR1CCR8CYP11B2CYP11B1 | |
| SCHEMBL3661584 | 0.77 | GABRG2 (0.47) | MEN1KMT2A | |
| SCHEMBL3421988 | 0.70 | CYP2A6 (0.67) | CYP2A6CCR1CCR8METAP2TGFBR1 | |
| SCHEMBL28453175 | 0.70 | CCR1 (0.73) | CYP2A6CCR1CCR8METAP2TGFBR1 | |
| SCHEMBL9356252 | 0.69 | CCR1 (0.64) | CYP2A6CCR1CCR8METAP2TGFBR1 | |
| SCHEMBL16675071 | 0.69 | CYP2A6 (0.53) | CYP2A6CYP11B2METAP2CYP11B1MEN1 | |
| SCHEMBL3665826 | 0.68 | CYP2A6 (0.44) | CYP2A6CYP11B2CYP11B1 | |
| SCHEMBL10374937 | 0.68 | CCR1 (0.56) | CYP2A6CCR1CCR8METAP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| EP-2242742-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | CYP2A6 916/4885CCR1 293/4885CCR8 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.